If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
In addition, seed collection is hampered by issues with the Convention on Biological Diversity, which regulates the ownership and international movement of genetic resources, but has been stuck in multilateral negotiations.
==== Androgenic ==== Androgen replacement therapy for men with low levels of testosterone, such as those associated with late-onset hypogonadism; also effective in improving libido for elderly males. Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty. Masculinizing hormone therapy for transgender men, other transmasculine people, and intersex people, by producing masculine secondary sexual characteristics such as a deeper voice, increased bone and muscle mass, masculine fat distribution, facial and body hair, and clitoral enlargement, as well as mental changes such as alleviation of gender dysphoria and increased sex drive.
In Table 1, "Name" refers to the common name of the reference, "Material" gives its chemical formula and phase, "Type of ratio" is the isotopic ratio reported in "Isotopic ratio", "δ" is the δ value of the material with indicated reference frame, "Type" is the category of the material using the notation of Gröening (2004) (discussed below), "Citation" gives the article(s) reporting the isotopic abundances on which the isotope ratio is based, and "Notes" are notes. The reported isotopic ratios reflect the results from individual analyses of absolute mass fraction, aggregated in Meija et al. (2016) and manipulated to reach the given ratios. Error was calculated as the square root of the sum of the squares of fractional reported errors, consistent with standard error propagation, but is not propagated for ratios reached through secondary calculation.
Sources: en.wikipedia.org
== Clinical significance == Human HGF plasmid DNA therapy of cardiomyocytes is being examined as a potential treatment for coronary artery disease as well as treatment for the damage that occurs to the heart after myocardial infarction. As well as the well-characterised effects of HGF on epithelial cells, endothelial cells and haemopoietic progenitor cells, HGF also regulates the chemotaxis of T cells into heart tissue. Binding of HGF by c-Met, expressed on T cells, causes the upregulation of c-Met, CXCR3, and CCR4 which in turn imbues them with the ability to migrate into heart tissue. HGF also promotes angiogenesis in ischemia injury. HGF may further play a role as an indicator for prognosis of chronicity for Chikungunya virus induced arthralgia. High HGF levels correlate with high rates of recovery. Excessive local expression of HGF in the breasts has been implicated in macromastia. HGF is also importantly involved in normal mammary gland development. HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast. Increased expression of HGF has been associated with the enhanced and scarless wound healing capabilities of fibroblast cells isolated from the oral mucosa tissue.
Most such markets do not trade in wild or exotic animals, but some that do have been linked to outbreaks of zoonotic diseases including COVID-19, H5N1 avian flu, severe acute respiratory syndrome (SARS), and mpox. Several countries have banned markets from holding wildlife. Media reports that fail to distinguish between food markets generally and those with live animals or wildlife, as well as insinuations of fostering wildlife smuggling, have been blamed for fueling Sinophobia related to the COVID-19 pandemic.
=== Insertion of transgenes === To integrate a gene fragment of interest into the Sendai virus genome, the following protocol might be used. The amplified gene fragment is inserted into a Sendai virus vector lacking the F protein (SeV/ΔF). The recovery and amplification of SeV/ΔF vectors proceed as follows: Transfection: 293T cells are transfected with the pSeV/ΔF template containing the transgene of interest, along with plasmids that encode the T7 RNA polymerase and the viral genes NP, P, F5R (a modified F protein), and L. Cultivation: Post-transfection, the cells are incubated and cultured for 1 to 3 days to produce the initial SeV/ΔF vector. Propagation: The vector is then propagated in LLC-MK2/F7/A cells, a specialized cell line of LLC-MK2 that expresses the Sendai virus F protein, in a medium that includes trypsin. Titer quantification: The titers of the harvested SeV vector are determined by measuring the cell infectious units (CIU) per milliliter through immunostaining with anti-SeV rabbit polyclonal serum.
Becoming a pathologist generally requires specialty-training after medical school, but individual nations vary somewhat in the medical licensing required of pathologists. In the United States, pathologists are physicians (D.O. or M.D.) who have completed a four-year undergraduate program, four years of medical school training, and three to four years of postgraduate training in the form of a pathology residency. Training may be within two primary specialties, as recognized by the American Board of Pathology: anatomical pathology and clinical pathology, each of which requires separate board certification. The American Osteopathic Board of Pathology also recognizes four primary specialties: anatomic pathology, dermatopathology, forensic pathology, and laboratory medicine. Pathologists may pursue specialised fellowship training within one or more subspecialties of either anatomical or clinical pathology. Some of these subspecialties permit additional board certification, while others do not. In the United Kingdom, pathologists are physicians licensed by the UK General Medical Council. The training to become a pathologist is overseen by the Royal College of Pathologists. After four to six years of undergraduate medical study, trainees proceed to a two-year foundation program. Full-time training in histopathology currently lasts between five and five and a half years, encompassing specialist training in surgical pathology, cytopathology, and autopsy pathology.
Sources: en.wikipedia.org
== Further reading == Burger, R., U.S. patent 872,795, "Double walled vessel with a space for a vacuum between the walls," December 3, 1907. Sella, Andrea (August 2008). "Dewar's Flask". Chemistry World: 75. Retrieved 2008-08-30.
=== CMOS image sensor === The invention of CMOS image sensors used in products such as mobile phones and GoPro action cameras traces back to NASA JPL scientist Eric Fossum who wanted to miniaturize cameras for interplanetary missions. Fossum invented CMOS image sensors that have become NASA's most ubiquitous spinoff technology, enabling the use of digital cameras in mobile phones (camera phones). Fossum found a way to reduce the signal noise that had plagued earlier attempts at CMOS imagers, applying a technique called intra-pixel charge transfer with correlated double sampling that results in a clearer image. This led to the creation of CMOS active pixel sensors, which are used today in all smartphone cameras and many other applications.
The medal for the Nobel Peace Prize was designed by the Norwegian sculptor Gustav Vigeland in 1901. Vigeland's profile sculpture of Alfred Nobel differs from Lindberg's. The dies for Vigeland's peace medal were made by Lindberg as Vigeland was not an engraver. The reverse of the medal features three men in a 'fraternal bond' and the inscription 'Pro pace et fraternitate gentium' ("For the peace and brotherhood of men"). The edge of the medal is inscribed with the year of its awarding, with the name of its recipient and "Prix Nobel de la Paix".
=== Variation === The two lobes differ slightly in size, with the left lobe usually higher than the right. Thymic tissue may be found scattered on or around the gland, and occasionally within the thyroid. The thymus in children stretches variably upwards, at times to as high as the thyroid gland.
Heroin is produced from opium, which is regulated differently around the world. Unlike coca leaves in Peru—handled exclusively by the state monopoly, the National Coca Company (ENACO)—there is no state company dedicated to the commercialization of opium and its derivatives. While international treaties—such as the Single Convention on Narcotic Drugs (1961)—require strict state control or monopoly over the legal production and commercialization of opium for medical and scientific purposes, in practice, only a few countries maintain such a state monopoly today. Notably, India operates a state monopoly through the Government Opium and Alkaloid Factories (GOAF), also known as Opium and Alkaloid Works, which is responsible for processing raw opium into alkaloids for the pharmaceutical industry and managing the legal opium trade for medical and scientific use. Legal opium production in India, as well as in countries such as Turkey, Australia, France, Japan, and the UK, supplies licensed pharmaceutical manufacturers under close supervision to prevent diversion to illicit markets.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.